Valuation: Astellas Pharma Inc.

Market Cap 4,50600Cr 2.85TCr 2.56TCr 2.36TCr 2.13TCr 3.99TCr 2,71800Cr 4.06TCr 28TCr 11TCr 1,42300Cr 11TCr 10TCr P/E 2027 *
11.4x
P/E 2028 * 12.4x
Enterprise Value 4,44700Cr 2.82TCr 2.52TCr 2.33TCr 2.11TCr 3.94TCr 2,68300Cr 4TCr 28TCr 11TCr 1,40400Cr 11TCr 10TCr EV / Sales 2027 *
1.87x
EV / Sales 2028 * 1.82x
Free-Float
98.92%
Yield 2027 *
3.19%
Yield 2028 * 3.31%
1 day+0.76%
1 week+1.46%
Current month+10.57%
1 month+8.11%
3 months+14.70%
6 months+12.68%
Current year+20.39%
1 week 15.77
Extreme 15.77
16.48
1 month 13.48
Extreme 13.48
16.48
Current year 12.82
Extreme 12.8175
17.35
1 year 10.05
Extreme 10.05
17.35
3 years 8.37
Extreme 8.37
17.35
5 years 8.37
Extreme 8.37
18.18
10 years 8.37
Extreme 8.37
18.46
Manager TitleAgeSince
Chief Executive Officer 64 10/02/2023
Director of Finance/CFO 55 01/11/2023
Compliance Officer - 01/04/2025
Director TitleAgeSince
Chairman 66 10/02/2023
Director/Board Member 64 01/06/2019
Director/Board Member 59 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%+1.46% - - 2.85TCr
+6.63%+5.13%+68.86%+145.20% 1,22400Cr
+1.53%+2.84%+47.48%+89.01% 66TCr
+1.68%+1.96%+29.16%+109.31% 51TCr
+0.47%+3.04%+53.92%+66.93% 39TCr
+3.83%-0.62%+69.01%+42.32% 36TCr
+0.79%+3.97%+34.59%+57.25% 30TCr
+3.72%+5.40%+7.73%+32.28% 27TCr
+1.97%+3.01%+57.91%+76.14% 25TCr
+4.03%+5.36%+39.76%+116.14% 21TCr
Average +1.74%+2.59%+45.38%+81.62% 46.41TCr
Weighted average by Cap. +1.59%+3.04%+50.68%+96.47%

Financials

2027 *2028 *
Net sales 2,37500Cr 1.5TCr 1.35TCr 1.24TCr 1.12TCr 2.1TCr 1,43300Cr 2.14TCr 15TCr 5.92TCr 75TCr 5.65TCr 5.53TCr 2,21300Cr 1.4TCr 1.26TCr 1.16TCr 1.05TCr 1.96TCr 1,33500Cr 1.99TCr 14TCr 5.51TCr 70TCr 5.26TCr 5.15TCr
Net income 38TCr 239.32Cr 214.35Cr 197.76Cr 178.96Cr 334.63Cr 23TCr 340.04Cr 2.36TCr 941.23Cr 12TCr 898.13Cr 879Cr 35TCr 219.23Cr 196.37Cr 181.16Cr 163.94Cr 306.55Cr 21TCr 311.51Cr 2.16TCr 862.25Cr 11TCr 822.76Cr 805.25Cr
Net Debt -5.93TCr -38Cr -34Cr -31Cr -28Cr -53Cr -3.58TCr -53Cr -370.36Cr -147.75Cr -1.87TCr -140.99Cr -137.98Cr -48TCr -304.5Cr -272.74Cr -251.62Cr -227.7Cr -425.79Cr -29TCr -432.67Cr -3TCr -1.2TCr -15TCr -1.14TCr -1.12TCr
Projected Income Statement - Annual - Astellas Pharma Inc.
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
29/26/29 $16.00 +0.76% 72,103
28/26/28 $15.88 -0.38% 68,334
27/26/27 $15.94 -2.03% 97,190
26/26/26 $16.27 +2.01% 60,038
23/26/23 $15.95 +1.14% 95,873
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Astellas Pharma Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,513.00JPY
Average target price
2,536.43JPY
Spread / Average Target
+0.93%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Astellas Pharma Inc.